Metabolic control of recombinant monoclonal antibody N‐glycosylation in GS‐NS0 cells
Abstract
Variable N‐glycosylation at Asn 297 in the Fc region of recombinant therapeutic immunoglobulin G (IgG) molecules, specifically terminal galactosylation and sialylation, may affect both pharmacokinetic behavior and effector functions of recombinant therapeutic antibodies. We investigated the hypothesis that IgG Fc glycosylation can be controlled by manipulation of cellular nucleotide‐sugar metabolism. In control cultures, N‐glycans associated with the Fc domain of a recombinant humanized IgG1 produced by GS‐NS0 cells in culture were predominantly biantennary, variably β‐galactosylated (average 0.3 mol galactose complex N‐glycan−1) structures with no bisecting N‐acetylglucosamine residues, sialylation, or α1,3‐linked galactosylation evident. However, a variable proportion (5% to 15%) of high‐mannose (Man5 to Man9) oligosaccharides were present. To manipulate the cellular content of the nucleotide sugar precursor required for galactosylation, UDP‐Gal, we included either 10 m M glucosamine or 10 m M galactose in the culture medium. In the case of the former, a 17‐fold increase in cellular UDP‐N‐acetylhexosamine content was observed, with a concomitant reduction (33%) in total UDP‐hexose, although the ratio of UDP‐Glc:UDP‐Gal (4:1) was unchanged. Associated with these alterations in cellular UDP‐sugar content was a significant reduction (57%) in the galactosylation of Fc‐derived oligosaccharides. The proportion of high‐mannose‐type N‐glycans (specifically Man5, the substrate for N‐acetylglucosaminyltransferase I) at Asn 297 was unaffected. In contrast, inclusion of 10 m M galactose in culture specifically stimulated UDP‐Gal content almost five‐fold. However, this resulted in only a minimal, insignificant increase (6%) in β1,4‐galactosylation of Fc N‐glycans. Sialylation was not improved upon the addition of the CMP–sialic acid (CMP‐SA) precursor N‐acetylmannosamine (20 m M), even with an associated 44‐fold increase in cellular CMP‐SA content. Analysis of recombinant IgG1 Fc glycosylation during batch culture showed that β1,4‐linked galactosylation declined slightly during culture, although, in the latter stages of culture, the release of proteases and glycosidases by lysed cells were likely to have contributed to the more dramatic drop in galactosylation. These data demonstrate: (i) the effect of steric hindrance on Fc N‐glycan processing; (ii) the extent to which alterations in cellular nucleotide‐sugar content may affect Fc N‐glycan processing; and (iii) the potential for direct metabolic control of Fc N‐glycosylation. © 2001 John Wiley & Sons, Inc. Biotechnol Bioeng 75: 239–251, 2001.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Approaches based on supplementation of cell culture media with precursors of the sialic acid pathway such as CMP-sialic acid, ManNAc and NeuNAc have limited and still debated effects.
“Some of these approaches are based on the supplementation of cell culture media with different precursors of the sialic acid pathway, such as CMP-sialic acid, ManNAc and NeuNAc, but their effects are limited and still debated (Gu and Wang, 1998;Baker et al., 2001;Hills et al., 2001;Bork et al., 2009;Hossler et al., 2009;Wong et al., 2010;Kildegaard et al., 2016).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Hills et al., 2001
Cites
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296 · see citing works
- Authors
- Hills, A. E., Patel, A., Boyd, P., & James, D. C.
- Affiliations
- University of Kent (GB)
- ORCID
- James, David C.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2001-08-28
- Volume
- 75
- Issue
- 2
- Pages
- 239-251
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2083441961
- Cited by
- 127
- References
- 1
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 4 · 2018: 12 · 2017: 9 · 2016: 8 · 2015: 10 · 2014: 10 · 2013: 7 · 2012: 5
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biotechnology and Bioengineering (publishedVersion)
- PubMed (publishedVersion)
- Kent Academic Repository (University of Kent) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Keywords
- N-glycosylation, Fc glycosylation, IgG1, monoclonal antibodies, nucleotide sugar metabolism, UDP-galactose, UDP-N-acetylhexosamine, sialylation, CMP-sialic acid, N-acetylmannosamine, galactose supplementation, high-mannose glycans, N-acetylglucosaminyltransferase I, humanized monoclonal antibody
- MeSH terms
- Amidohydrolases, Animals, Antibodies, Monoclonal, Carrier Proteins, Chromatography, High Pressure Liquid, Cytidine Monophosphate N-Acetylneuraminic Acid, Galactose, Glucosamine, Glycoproteins, Glycosylation, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Mannose, Membrane Proteins, Nucleotides, Polysaccharides, Recombinant Proteins, Tumor Cells, Cultured, Cell Adhesion Molecules, Culture Media, Serum-Free, Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase, Mice, ortho-Aminobenzoates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review